06.03.2020 • News

McDermott Progresses Lummus Sale to Chatterjee/Rhone

McDermott Progresses Lummus Sale to Chatterjee/Rhone (c) McDermott
McDermott Progresses Lummus Sale to Chatterjee/Rhone (c) McDermott

Engineering and construction group McDermott will move forward with its previously announced sale of subsidiary Lummus Technology to a partnership of The Chatterjee Group and Rhone Capital, having failed to attract higher bids at auction.

In January, McDermott entered into a share and asset purchase agreement to sell the business to the partnership as the “stalking horse bidder” for a base price of $2.725 billion, subject to receiving higher or better bids through a court-supervised auction.

The US company confirmed it did not receive a higher or better bid during the solicitation period and the auction previously scheduled for Mar. 9 will not take place.

McDermott added that it will have the option to retain or purchase a 10% common equity ownership interest in the entity that buys Lummus Technology.

The sale is part of McDermott’s Chapter 11 bankruptcy process, which will see it implement a major restructuring that is expected to wipe out more than $4.6 billion of debt. Proceeds are expected to repay McDermott’s debtor-in-possession (DIP) financing in full as well as fund emergence costs and provide cash to the balance sheet for long-term liquidity.

A hearing to confirm the sale will take place on Mar. 12.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.